Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation

Bone Marrow Transplantation volume 40, pages 431–435 (2007)Cite this article

Abstract

Graft failure is a life-threatening complication of allogeneic stem cell transplantation (SCT). We assessed the feasibility of performing a second SCT after such failure when fludarabine and antithymocyte globulin (ATG) are used for non-myeloablative conditioning and tacrolimus for graft-versus-host disease (GVHD) prophylaxis. Nine patients with SCTs for various hematologic malignancies were enrolled, eight with primary and one with secondary graft failure. The median time between the first and second SCT was 53 days. Eight patients had the same donor for their second SCT, and one had a cord blood transplant. Three patients were not evaluable because of early death; the other six had evidence of donor cell engraftment. Six of the nine patients developed acute grade II–IV GVHD, the main cause of death. Overall, we found that fludarabine and ATG conditioning before a second SCT allows engraftment of donor hematopoiesis. Future studies should include more intense GVHD prophylaxis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.

    Article  CAS  PubMed  Google Scholar 

  2. Donohue J, Homge M, Kernan NA . Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated marrow donor. Blood 1993; 82: 1023–1029.

    CAS  PubMed  Google Scholar 

  3. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990; 322: 485–494.

    Article  CAS  PubMed  Google Scholar 

  4. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.

    Article  CAS  PubMed  Google Scholar 

  5. Storb R, Prentice RL, Thomas ED . Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977; 296: 61–66.

    Article  CAS  PubMed  Google Scholar 

  6. Wolff SN . Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002; 29: 545–552.

    Article  CAS  PubMed  Google Scholar 

  7. Nemunaitis J, Singer JW, Buckner CD, Durnam D, Epstein C, Hill R et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245–253.

    CAS  PubMed  Google Scholar 

  8. Weisdorf DJ, Verfaillie CM, Davies SM, Filipovich AH, Wagner Jr JE, Miller JS et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 1995; 85: 3452–3456.

    CAS  PubMed  Google Scholar 

  9. Fouillard L, Deconinck E, Tiberghien P, Deschaseaux ML, Solary E, Mugneret F et al. Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 943–946.

    Article  CAS  PubMed  Google Scholar 

  10. Remberger M, Ringden O, Ljungman P, Hagglund H, Winiarski J, Lonnqvist B et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 22: 73–78.

    Article  CAS  PubMed  Google Scholar 

  11. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Hutton JJ et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457–459.

    CAS  PubMed  Google Scholar 

  12. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419–2423.

    Article  PubMed  Google Scholar 

  13. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941–949.

    CAS  PubMed  Google Scholar 

  14. Chung IJ, Lee JJ, Park MR, Kook H, Cho SH, Hwang TJ et al. Allogeneic peripheral blood stem cell rescue of late graft failure after bone marrow transplantation in patients with aplastic anemia. J Korean Med Sci 2002; 17: 468–474.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Thomas E, Storb R, Clift RA, Johnson FL, Neiman PE, Lerner KG et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843.

    Article  CAS  PubMed  Google Scholar 

  16. Grandage VL, Cornish JM, Pamphilon DH, Potter MN, Steward CG, Oakhill A et al. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated bone marrow transplantation. Bone Marrow Transplant 1998; 21: 687–690.

    Article  CAS  PubMed  Google Scholar 

  17. Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 2000; 111: 292–302.

    Article  CAS  PubMed  Google Scholar 

  18. Mrsic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G et al. Second HLA-identical sibling transplants for leukemic recurrence. Bone Marrow Transplant 1992; 80: 33–39.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    E Jabbour, G Rondon, P Anderlini, S A Giralt, D R Couriel, R E Champlin & I F Khouri

Authors
  1. E Jabbour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Rondon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Anderlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D R Couriel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I F Khouri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I F Khouri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jabbour, E., Rondon, G., Anderlini, P. et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40, 431–435 (2007). https://doi.org/10.1038/sj.bmt.1705760

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705760

Keywords

This article is cited by

Search

Advanced search

Quick links